Top

Published in:

01-07-2019 | Original Article

Cholecalciferol for the prophylaxis against recurrent urinary tract infection among patients with benign prostatic hyperplasia: a randomized, comparative study

Authors: Ahmed S. Safwat, Ahmad Hasanain, Ahmed Shahat, Mostafa AbdelRazek, Hazem Orabi, Samir K. Abdul Hamid, Amany Nafee, Sally Bakkar, Mohamed Sayed

Published in: World Journal of Urology | Issue 7/2019

Abstract

Purpose

To explore the role of cholecalciferol for the prophylaxis against recurrent urinary tract infection (UTI) in patients with benign prostatic hyperplasia (BPH).

Methods

Our randomized, uncontrolled prospective study included 389 naïve BPH patients with moderate/severe symptoms, consecutively. The patients were randomly allocated to two groups; group-A included 193 patients who received tamsulosin, while group-B included another 196 patients who received tamsulosin with cholecalciferol. The study population was followed up for 2 years after the start of the treatment. For all the patients enrolled, clinical evaluation, imaging studies (abdominal and trans-rectal ultrasonography), and laboratory investigations [including urinalysis, urine culture with antibiotic susceptibility testing for positive cultures and estimation of prostate-specific antigen (PSA) level] were provided.

Results

The incidence rate of recurrent UTI was 9% among the study population; it was significantly higher among group-A patients compared to those of group-B (13.5% vs. 4.6%, p 0.003, OR 2.7, 95% CI 1.5–4.3). Compared to patients of group-A, those of group-B developed a significantly lower level of PSA at the end of treatment period (0.16 ± 0.03 ng/mL vs. 0.27 ± 0.08 ng/mL, p 0.043, OR 1.9, 95% CI 1.2–6.8).

Conclusions

Adjuvant cholecalciferol supplementation may be protective against recurrent UTI among patients with BPH receiving tamsulosin therapy without extra adverse effects.

Available only for authorised users

Schaeffer AJ, Nicolle LE (2016) Urinary tract infections in older men. N Engl J Med 374:562–571CrossRefPubMed

Berry SJ, Coffey DS, Walsh PC et al (1984) The development of human benign prostatic hyperplasia with age. J Urol 132:474–479CrossRefPubMed

Harper M, Fowlis G (2007) Management of urinary tract infections in men. Trends Urol Gynecol Sex Health 12:30–35CrossRef

Pourmand G, Abedi AR, Karami AA et al (2010) Urinary infection before and after prostatectomy. Saudi J Kidney Dis Transpl 21:290–294PubMed

Holick MF, Binkley NC, Bischoff-Ferrari HA et al (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96:1911–1930CrossRef

Bhalla AK, Amento EP, Clemens TL et al (1983) Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab 57:1308–1310CrossRef

White JH (2008) Vitamin D signaling, infectious diseases, and regulation of innate immunity. Infect Immun 76:3837–3843CrossRefPubMedPubMedCentral

Juzeniene A, Ma LW, Kwitniewski M et al (2010) The seasonality of pandemic and non-pandemic influenzas: the roles of solar radiation and vitamin D. Int J Infect Dis 14:e1099–e1105CrossRefPubMed

Kearns MD, Alvarez JA, Seidel N et al (2015) Impact of vitamin D on infectious disease. Am J Med Sci 349:245–262CrossRefPubMedPubMedCentral

10.

van der Starre WE, van Nieuwkoop C, Paltansing S et al (2011) Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection. J Antimicrob Chemother 66:650–656CrossRefPubMed

11.

Lipsky BA (1989) Urinary tract infections in men. Epidemiology, pathophysiology, diagnosis, and treatment. Ann Intern Med 110:138–150CrossRefPubMed

12.

Ulleryd P, Zackrisson B, Aus G et al (1999) Prostatic involvement in men with febrile urinary tract infection as measured by serum prostate-specific antigen and transrectal ultrasonography. BJU Int 84:470–474CrossRefPubMed

13.

Adorini L (2005) Intervention in autoimmunity: the potential of vitamin D receptor agonists. Cell Immunol 233:115–124CrossRefPubMed

14.

Norman AW (2006) Vitamin D receptor: new assignments for an already busy receptor. Endocrinology 147:5542–5548CrossRefPubMed

15.

Chromek M, Slamová Z, Bergman P et al (2006) The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat Med 12:636–641CrossRefPubMed

16.

Hertting O, Holm Å, Lüthje P et al (2010) Vitamin D induction of the human antimicrobial Peptide cathelicidin in the urinary bladder. PLoS One 5:e15580CrossRefPubMedPubMedCentral

17.

Bikle DD (2008) Vitamin D and the immune system: role in protection against bacterial infection. Curr Opin Nephrol Hypertens 17:348–352CrossRefPubMed

18.

Eklund D, Persson HL, Larsson M et al (2013) Vitamin D enhances IL-1β secretion and restricts growth of Mycobacterium tuberculosis in macrophages from TB patients. Int J Mycobacteriol 2:18–25CrossRefPubMed

19.

Gombart AF, Borregaard N, Koeffler HP (2005) Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J 19:1067–1077CrossRefPubMed

20.

Jorde R, Sollid ST, Svartberg J et al (2016) Prevention of urinary tract infections with vitamin D supplementation 20,000 IU per week for five years results from an RCT including 511 subjects. Infect Dis (Lond) 48:823–828CrossRef

21.

Espinosa G, Esposito R, Kazzazi A et al (2013) Vitamin D and benign prostatic hyperplasia—a review. Can J Urol 20:6820–6825PubMed

22.

Adorini L, Penna G, Fibbi B et al (2010) Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia. Ann NY Acad Sci 1193:146–152CrossRefPubMed

23.

Kristal AR, Arnold KB, Schenk JM et al (2008) Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol 167:925–934CrossRefPubMed

24.

Colli E, Rigatti P, Montorsi F et al (2006) BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur Urol 49:82–86CrossRefPubMed

25.

Peehl DM, Skowronski RJ, Leung GK et al (1994) Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 54:805–810PubMed

26.

Murthy S, Agoulnik IU, Weigel NL (2005) Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Prostate 64:362–372CrossRefPubMed

27.

Yee SW, Campbell MJ, Simons C (2006) Inhibition of vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells. J Steroid Biochem Mol Biol 98:228–235CrossRefPubMed

28.

Penna G, Fibbi B, Amuchastegui S et al (2009) The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-κB pathways. Prostate 69:480–493CrossRefPubMed

29.

Badalian SS, Rosenbaum PF (2010) Vitamin D and pelvic floor disorders in women: results from the National Health and Nutrition Examination Survey. Obstet Gynecol 115:795–803CrossRefPubMed

30.

Murphy AB, Nyame YA, Batai K et al (2017) Does prostate volume correlate with vitamin D deficiency among men undergoing prostate biopsy? Prostate Cancer Prostatic Dis 20:55–60CrossRefPubMed

Title: Cholecalciferol for the prophylaxis against recurrent urinary tract infection among patients with benign prostatic hyperplasia: a randomized, comparative study
Authors: Ahmed S. Safwat
Ahmad Hasanain
Ahmed Shahat
Mostafa AbdelRazek
Hazem Orabi
Samir K. Abdul Hamid
Amany Nafee
Sally Bakkar
Mohamed Sayed
Publication date: 01-07-2019
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 7/2019
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-018-2536-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cholecalciferol for the prophylaxis against recurrent urinary tract infection among patients with benign prostatic hyperplasia: a randomized, comparative study

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2019

Versatile algorithmic midline approach to perineal urethrostomy for complex urethral strictures

Aquablation of the prostate: single-center results of a non-selected, consecutive patient cohort

Fiducial markers: can the urologist do better?

Does mechanical morcellation of large glands compromise incidental prostate cancer detection on specimen analysis? A pathological comparison with open simple prostatectomy

Diagnosis and management of nocturia in current clinical practice: who are nocturia patients, and how do we treat them?

Prediction of biochemical failure using prostate-specific antigen half-life in patients with adverse pathologic features after radical prostatectomy